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Abstract
In 1957, Wallace Brigden published an article on the Lancet, such as uncommon
myocardial diseases: the non-coronary cardiomyopathy. In this article, he men-
tioned that “the term cardiomyopathy is used here to indicate isolated noncoronary
myocardial disease.” Then “cardiomyopathy” has become a commonly used term in
the cardiovascular field, and has been defined and classified by many researchers
and academic societies. The basic concept of cardiomyopathy is a group of diseases
with mechanical and/or electrophysiological dysfunction of the ventricles, and car-
diomyopathy is distinguished with normal ischemic heart disease, valvular disease,
and hypertensive heart disease. It can often cause heart failure and cardiac death. In
this chapter, we describe the classification, details, and treatment of cardiomyopa-
thy, and iPS cell from pathological myocardium.
Keywords: cardiomyopathy, classification, dilated cardiomyopathy, differentiation
of dilated cardiomyopathy, hypertrophic cardiomyopathy, treatment of
cardiomyopathy, human- induced pluripotent stem cell
1. Introduction
Goodwin et al. stated that, “the term cardiomyopathy has come into use to
describe disorders of the heart, not primarily due to rheumatic, hypertensive,
coronary-artery, thyroid, or congenital disease” [1]. They mentioned that the defi-
nition of cardiomyopathy is not completely satisfactory, but cardiomyopathy is a
subacute or chronic disorder of the myocardium of unknown or unclear etiology,
often with associated endocardium and sometimes with pericardial involvement.
However, atherosclerosis does not cause cardiomyopathy. They described that the
classification of cardiomyopathy consists of congestive heart failure including
dilated, constrictive, restrictive, obstructive, and hypertrophic cardiomyopathy.
Inheriting the concept of cardiomyopathy proposed by Goodwin et al., in 1980, the
World Health Organization (WHO)/International Society and Federation of Cardi-
ology (ISFC) task force defined “cardiomyopathies are heart muscle diseases of
unknown cause” and classified into dilated cardiomyopathy, hypertrophic cardio-
myopathy, restrictive cardiomyopathy and unclassifiable cardiomyopathy [2]. In
1982, arrhythmogenic right ventricular dysplasia (formerly known as ARVC, cur-
rently known as arrhythmogenic cardiomyopathy), which is an inherited form of
heart disease characterized pathologically by fibrofatty myocardial replacement and
clinically by prominent ventricular arrhythmias and impairment of ventricular
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systolic function, was reported [3]. Since arrhythmogenic right ventricular dyspla-
sia means a genetically determined heart muscle disorder, the term dysplasia was
replaced by cardiomyopathy. In 1995, the WHO/ISFC task force newly defined
cardiomyopathies as “diseases of the myocardium associated with cardiac dysfunc-
tion.” classified into dilated cardiomyopathy, hypertrophic cardiomyopathy,
restrictive cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy,
unclassified cardiomyopathy [4]. And then, they used the term specific cardiomy-
opathy for heart muscle disease that is clearly associated with specific cardiac or
systemic disorders.
In 2006, the American Heart Association (AHA) proposed a definition and
classification of cardiomyopathy as following: “Cardiomyopathies are a heteroge-
neous group of diseases of the myocardium associated with mechanical and/or
electric dysfunction that usually (but not invariably) exhibit inappropriate ventric-
ular hypertrophy or dilatation and are due to a variety of causes that frequently are
genetic. Cardiomyopathies either are confined to the heart or are part of generalized
systemic disorders” [5]. AHA cardiomyopathy classification roughly divided into
primary cardiomyopathy which has main lesion in the heart, and secondary cardio-
myopathy which is a systemic heart lesion. Primary cardiomyopathy is classified
into three categories: hereditary, mixed (hereditary and acquired), and acquired
(Figure 1). Genetic cardiomyopathy includes HCM, ARVC, LVNC, glucose accu-
mulation disease, cardiac conduction disorders, mitochondrial cardiomyopathy,
and ion channel disease such as LQTS, Brugada, SQTS, CPVT, IVF (Table 1). The
ion channelopathy are primary electrical diseases without gross or histopathological
abnormalities in which the functional and structural myocardial abnormalities
responsible for arrhythmogenesis are at the molecular level in the cell membrane
itself. Therefore, the basic pathological abnormality in these diseases is not identi-
fiable by either conventional noninvasive imaging or myocardial biopsy during life
or even by autopsy examination of tissue. This is a new concept of cardiomyopathy
adopted in the AHA classification. Mixed cardiomyopathy includes DCM, restric-
tive (non-hypertrophied and non-dilated), and acquired cardiomyopathy includes
myocarditis, stress-provoked (tako-tsubo), peripartum, tachycardia-induced,
Figure 1.
Definition and classification of cardiomyopathy proposed by AHA in 2006. Modified citation from Ref. [5].*
See Table 1. © 2006 American Heart Association, Inc.
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infants of insulin-dependent diabetic mothers. Tables 2 and 3 display secondary
cardiomyopathy that is almost equivalent to the previous specific cardiomyopathy
of the WHO/ISFC task force. This looks like a classification from a genetic, biomo-
lecular point of view.
On the other hand, in 2008 European Society of Cardiology (ESC) defined a
cardiomyopathy as, “a myocardial disorder in which the heart muscle is structurally
and functionally abnormal, in the absence of coronary artery disease, hypertension,
valvular disease and congenital heart disease sufficient to cause the observed myo-
cardial abnormality” [6]. Cardiomyopathies are grouped into specific
ARVC: Arrhythmogenic Right Ventricular Cardiomyopathy
CPVT: Catecholaminergic Polymorphic Ventricular Tachycardia
DCM: Dilated Cardiomyopathy
HCM: Hypertrophic Cardiomyopathy
IVF: Idiopathic Ventricular Fibrillation
LVNC: Left Ventricular Noncompaction Cardiomyopathy





Infiltrative (Accumulation of abnormal substances between myocytes (ie, extracellular))
Amyloidosis (primary, familial autosomal dominant†, senile, secondary forms)
Gaucher disease (Genetic (familial) origin)
Hurler’s disease (Genetic (familial) origin)
Hunter’s disease (Genetic (familial) origin)
Storage (Accumulation of abnormal substances within myocytes (ie, intracellular))
Hemochromatosis
Fabry’s disease (Genetic (familial) origin)
Glycogen storage disease (type II, Pompe) (Genetic (familial) origin)
Niemann-Pick disease (Genetic (familial) origin)
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Drugs, heavy metals, chemical agents
Endomyocardial
Endomyocardial fibrosis










morphological and functional phenotypes. Each phenotype is then sub-classified
into familial and non-familial forms (Figure 2). This classification is an extension of
the WHO/ISFC classification, with genetic and non-genetic classifications based on
morphological and functional abnormalities. In 2018, Japanese Circulation Society
(JCS) has revised the cardiomyopathy clinical practice guidelines [7]. JCS defined a
cardiomyopathy as so-called primary cardiomyopathy, is divided into four types:
hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ven-
tricular cardiomyopathy, and restrictive cardiomyopathy (Figure 3). Some of the
Cardiofacial
Noonan syndrome (Genetic (familial) origin)
Lentiginosis (Genetic (familial) origin)
Neuromuscular/neurological
Friedreich’s ataxia (Genetic (familial) origin)
Duchenne-Becker muscular dystrophy (Genetic (familial) origin)
Emery-Dreifuss muscular dystrophy (Genetic (familial) origin)
Myotonic dystrophy (Genetic (familial) origin)
Neurofibromatosis (Genetic (familial) origin)
Tuberous sclerosis (Genetic (familial) origin)
Nutritional deficiencies








Consequence of cancer therapy
Anthracyclines: doxorubicin (adriamycin), daunorubicin
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Radiation
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four basic pathologies of primary cardiomyopathy overlap and are often difficult to
distinguish from each other. Diagnosis of these four primary cardiomyopathies
should be confirmed after distinguishing secondary cardiomyopathy as much as
possible. Cardiomyopathy that cannot be classified into four basic pathological
conditions at present is called unclassifiable cardiomyopathy. The classification of
JCS may be close to that of ESC.
Figure 2.
Definition and classification of cardiomyopathy proposed by ESCA in 2008. Modified citation from Ref. [6].
* See Table 1.
Figure 3.
Revised definition and classification of cardiomyopathy proposed by JSC in 2018. Modified citation from Ref.




In 2013, Arbustini et al proposed the MOGE (S) classification of cardiomyopathy
approved by the World Heart Federation [8] (Figure 4). This is a classification
system similar to the TMM system, which is a system for staging cancers in oncol-
ogy. This is a classification that integrates cardiomyopathy by morphology and
function (M:Morpho-functional phenotype), affected organs (O:Organ/system
involvement), gene mutation (G:Genetic inheritance pattern), cause and pathology
E: Etiology), and severity (S: Stage) and obtains information necessary for treat-
ment in an easy-to-understand manner. In this way, there are many cardiomyopa-
thy classifications in the world, but it is difficult to say that they are sufficiently
unified, including the usage of terms.
2. Dilated cardiomyopathy (DCM)
DCM is a group of diseases characterized by myocardial contractile dysfunction
and dilatation of the left ventricular lumen and has a poor prognosis and progressive
disease with symptoms of chronic heart failure and repeated acute deterioration. It
also causes sudden death due to fatal arrhythmias. The initial report on the prevalence
of DCM was published in 1989. This study was analyzed using data fromMayo Clinic
and identified 45 new cases of DCM in Olmsted County, Minnesota between 1975 and
1984. The incidence of DCM doubled from 3.9 per 100,000 person-years to 7.9 per
100,000 person-years during the first 5 years. The prevalence of DCM in people
younger than 55 years was 17.9 per 100,000, and more than one-third of them were
in New York Heart Association functional III or IV at diagnosis [9].
The etiology of DCM has been unknown for a long time, but it has been divided
into familial and non-familial categories. In particular, most cases of adult-onset
DCM are considered to be caused by both familial and non-familial factors.
Figure 4.
The MOGE(S) nomenclature of cardiomyopathy. Modified citation from Ref. [8].
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Advances in molecular genetic analysis have revealed causative mutations of DCM
in more than 60 genes and truncating mutations in the titin (TTN) gene were
shown to be present 25% of familial or severe transplant DCM cases [10]. In another
report, truncation of the TTN gene was found in about 13% of non-familial DCM
cases, but also 2% of the general population [11]. Recently, a polygenic risk score
has been developed to predict the cumulative effect of multiple susceptibility genes
identified by genome-wide association studies using mathematical models, and it
has become clear that genetic variation can be affected by exogenous or environ-
mental factors [12]. In addition, the clinical impact differed by genetic mutation,
DCM patients with truncating mutations in TTN having a milder disease phenotype
at baseline and a higher incidence of reverse remodeling compared with patients
with a pathogenic lamin A/C (LMNA) mutation [13], which is one of the DCM with
poor prognosis due to the risk of sudden death [14]. Recently, other mutations such
as carriers of a specific phospholamban (PLN) mutation or truncating filamin C
(FLNC) mutations have been reported as a risk of sudden death in DCM patients
[15, 16]. The causes of non-familial DCM are still unknown. The etiology is consid-
ered to be inflammation and necrosis of cardiomyocytes caused by infectious fac-
tors such as viruses and bacteria and non-infectious factors such as autoimmunity,
drugs and stress. In fact, it has been reported that viral genomes have been detected
in the tissues of patients diagnosed with DCM [17].
3. Differentiation of DCM
As mentioned above, DCM is defined as a group of diseases characterized by
diffuse contractility disorder and dilatation of the left ventricle. Therefore, it is
necessary to exclude specific heart muscle diseases for definitive diagnosis. Specific
heart muscle indicates ischemic cardiomyopathy, valvular heart disease, and
hypertensive heart disease, inflammatory heart disease, metabolic heart disease,
myocardial disease associated with neuromuscular disease or myocardial disease
with clear association with systemic disease [4].
3.1 Ischemic cardiomyopathy
Ischemic cardiomyopathy is caused by ischemia due to coronary atherosclerosis
and it is characterized by left ventricular dilatation and contractile dysfunction,
similar to DCM. Ischemic cardiomyopathy is the most common cause of heart
failure in clinical cases and should be excluded initially. In addition to a history of
ischemic heart disease, coronary angiography or coronary computed tomography is
necessary to be differentiated. If contrast medium is not available, scintigraphy can
be used as a substitute. In rare cases, left ventricular dysfunction such as DCM may
occur due to multiple vessel coronary artery spasm, even in the absence of coronary
artery stenosis. If this is suspected on symptoms, an acetylcholine provocation test
should be considered [18].
3.2 Hypertensive cardiomyopathy
Hypertensive cardiomyopathy is similar to DCM, which presents with systolic
dysfunction as a result of histological abnormalities such as left ventricular hyper-
trophy and myocardial cell hypertrophy, interstitial proliferation and perivascular
fibrosis due to persistent hypertensive conditions. It is a pathological condition and
is characterized by efferent hypertrophy with left ventricular enlargement. In addi-




due to sustained hypertension such as blood vessels and kidneys often contribute to
the onset of heart failure.
3.3 Amyloidosis Cardiomyopathy
Amyloidosis indicates a general team of diseases characterized by the extracel-
lular deposition of misfolded amyloid fibrils in organs. Clinically, it is roughly
divided into systemic amyloidosis in which multiple organs and peripheral nerves
are damaged, and focal amyloidosis in which amyloid deposits occur locally in an
organ or organs. Cardiac amyloidosis is one of the common infiltrative or restrictive
cardiomyopathies associated with an unfavorable prognosis. The pathophysiology
of amyloidosis is the misfolding of abnormal protein that is amyloid fibrils resulting
in its accumulation to extracellular on the affected tissues. Although there are
multiple causes of the misfolding, one of them is a gene mutation that encodes a
different amino-acid leading to the conformational change of protein [19].
Clinical outcome depends on the extent of tissue involvement and on the type of
amyloid fibril deposits. The major subtypes of systemic amyloidosis classified based
on the underlying etiologies are as follows: primary (AL) amyloidosis, Secondary
(AA) amyloidosis (or reactive amyloidosis), familial transthyretin-associated amy-
loidosis (ATTR or hereditary amyloidosis), dialysis-related amyloidosis, and senile
systemic amyloidosis. AL amyloidosis has an incidence of 1 case per 100,000
person-years in western countries. ATTR is a less common systemic type of amy-
loidosis with unknown incidence
Cardiac manifestations predominantly include symptoms of right heart failure.
Infiltration of amyloid fibrils results in stiffening and thickening of ventricles causing
decreased compliance and increased pressure altering the mechanics of ventricular
function manifesting as diastolic dysfunction. Furthermore, cytotoxic effects of amy-
loid fibrils result in apoptotic and fibrotic changes of the heart. Finally, these changes
lead to heart failure. Amyloid deposits to cardiac conduction system result in heart
block or arrhythmias [20]. Syncope due to heart block or arrhythmia may be a
marker of prognosis [20]. Atrial fibrillation (AF) is the most common arrhythmia
described in approximately 10%-20% of patients who have cardiac amyloidosis [21].
It is possible that patients of cardiac amyloidosis are completely asymptomatic or
may present with various signs and symptoms. Therefore, a diagnostic approach is
important in cases of suspected cardiac amyloidosis. Pseudoinfarction, which is low
voltage in limb leads and poor R wave progression in ECG, is one of the most
common electrocardiographic characteristics in cardiac amyloidosis. This finding
has been demonstrated in up to half of patients with AL [22]. Furthermore, amyloid
deposits also result in various arrhythmias, such as various heart blocks, AF, and
complex ventricular tachycardia [23].
The echocardiography is recommended in all patients with suspected amyloid-
osis, and findings include bilateral dilatation and thickening of ventricular wall and
valves, decreased diastolic filling, and classic granular sparkling appearance. The
wall thickness is attributed to infiltrative amyloid deposition instead of myocyte
hypertrophy [24]. Decreased left ventricular ejection fraction is of grim prognostic
significance [25]. Cardiovascular magnetic resonance imaging (CMR) is an impor-
tant diagnostic and prognostic tool in the assessment of severity of cardiac amy-
loidosis. Injury to the myocardium secondary to deposition of amyloid fibrils in the
interstitium denotes a reservoir for gadolinium accumulation leading to character-
istic late gadolinium enhancement (LGE) [26]. This technique has a sensitivity of
close to 80% and impressive specificity of 94% [27]. Strain analysis based on CMR
can be accomplished with the recent advances, a technique known as Displacement
Encoding with Stimulated Echoes with high sensitivity and specificity close to echo
8
Cardiomyopathy - Disease of the Heart Muscle
[28]. It is a highly precise modality and hold promises in generation of strain time
curves with “tissue tracking” techniques. Use of radiotracers has been used to
diagnose amyloidosis. Most commonly, 99mTc-DPD (technetium-3,3-
diphosphono-1,2-propanodicarboxylic acid) and 99mTc-PYP is used. As 99mTc-
PYP preferentially binds to ATTR relative to AL fibrils, this technique also serves as
an on invasive way to distinguish the aforementioned amyloidosis subtypes [29].
Biopsy with histopathology remains the gold standard showing deposition of amor-
phous deposits of amyloid fibrils.
Treatment can be divided into HF therapy, specific therapy for each amyloid-
osis. Chemotherapy is based on the concept of reducing the number of amyloid
fibrils and retarding the disease process. In AL, chemotherapy and autologous
hematopoietic stem cell transplant is the main stay of treatment. Chemotherapy in
AL is aimed at reducing free light chains. Bortezomib is a proteasome inhibitor that
induces rapid hematological response either alone or in combination with dexa-
methasone [30]. As mutant amyloid ATTR is produced in liver, orthotropic liver
transplantation is the established treatment since 1990. Transthyretin (TTR) tetra-
mer stabilizers (tafamidis and diflunisal) work by binding to TTR and by stabilizing
its normal tetrameric structure preventing amyloid fibril formation [31]. Drugs
such as tafamidis and diflunisal, could have role in the treatment of senile systemic
amyloidosis (SSA) which is amyloidosis that mainly affects the heart of the elderly.
3.4 Sarcoidosis
Sarcoidosis is a systemic inflammatory disease characterized by the formation of
granulomas in affected organs, especially the lungs. Diagnosis is challenging for
clinicians because various organs can be affected. The exact prevalence of cardiac
lesions in sarcoidosis is unknown due to ethnic differences, but the incidence of
sarcoidosis has been reported to 11-24 cases per 100,000 per a year in Scandinavian
countries and 1 case per 100,000 per a year [32, 33]. The incidence is higher in
women (45-60%) and the average age of diagnosis is younger in men (30-50 years)
compared to women (50-60 years) [34]. The etiology of sarcoidosis is unknown,
however, it has been reported that not only genetic factors but also living
environment and lifestyle are contributing factors [35]. The inflammatory
response in sarcoidosis is thought to involve autoimmunity, possibly including
autoantigens, although there are no specific diagnostic markers or biomarkers for
activity.
Cardiac sarcoidosis is present 2-7% of patients with sarcoidosis, and cardiac
sarcoidosis can occur without pulmonary or systemic involvement [36]. In the early
stages of the disease, ventricular wall thickening coinciding with regions of granu-
lomatous inflammation and interstitial edema is observed, and as inflammation
gradually fades and fibrosis of the lesions progresses, the base of the ventricular
septum often shows characteristic wall thinning. Regional hypokinesia of the left
and right ventricles and ventricular aneurysm are observed and if the lesion is
extensive, DCM-like pathology may be observed [37].
The detection rate of myocardial biopsies is low, and currently gadolinium-
enhanced cardiac magnetic resonance imaging is the optimal test for determining
the presence and extent of cardiac lesions. 18F-FDG-PET is useful for evaluating the
degree of granulomatous inflammation and activity of cardiac lesions [38].
3.5 Drug-induced cardiomyopathy
Drug-induced cardiomyopathy is commonly seen in clinical situations as a serious




a history of cancer treatment need to be asked about what kind of anticancer drug
treatment they have received and whether they have received radiation therapy.
The most commonly identified chemotherapeutic drugs with cardiotoxicity are
anthracyclines and these drugs are still used in clinical practice [39]. It has been
reported that cutoff value for anthracycline administration to affect cardiovascular
risk is 250 mg/m2 or higher, but even lower doses can cause cardiac dysfunction
[40, 41]. With the improvement of chemotherapy outcomes, the number of long-
term survivors of childhood cancer has increased and delayed drug-induced car-
diomyopathy often develops in adulthood after anthracycline treatment in child-
hood [42].
Trastuzumab (Herceptin) is a humanized IgG kappa monoclonal antibody that
targets the extracellular domain of human epidermal growth factor receptor 2
(HER2) [43]. The HER2 has been found to be amplified 2 to 20 times or more in
30% of breast cancer patients, and gene amplification has been reported to be a
significant predictor of both survival and time to recurrence [44]. Trastuzumab-
induced cardiomyopathy usually presents as an asymptomatic decrease in left ven-
tricular ejection fraction and can lead to complications such as heart failure, but the
cardiotoxicity is transient and reversible, in addition it isn’t dose-dependent as with
anthracyclines [45, 46].
To evaluate such drug-induced cardiomyopathy, American Society of Echocar-
diography has defined that cancer therapeutics-related cardiac dysfunction as
decrease in left ventricular ejection fraction (LVEF) or greater to less than 53%. In
addition, LVEF is reevaluated after 2 to 3 weeks and is considered reversible if the
decline is within 5% of baseline, and irreversible if the improvement in EF is less
than 10% and remains below 5% of baseline. In particular, it is recommended that
the LVEF and global strain be evaluated in combination [47]. Even in facilities that
do not have echocardiography, troponin I has been reported to be elevated indicat-
ing the possibility of cardiotoxicity and measurement of troponin I is also
recommended [48].
3.6 Myocarditis
Myocarditis is an inflammatory disease in which inflammation spreads to
cardiomyocytes. Most of them are viral infections, and adenovirus, enterovirus
including the coxsackievirus B, parvovirus, cytomegalovirus and HIV are the most
frequent as causative virus of myocarditis [49]. Bacteria that causes non-viral myo-
carditis include corynebacterium infection, streptococcal infection, tuberculosis,
Whipple’s disease, and Lyme carditis. The definitive diagnosis of myocarditis is
based on myocardial biopsy and histological diagnosis. A typical finding of myo-
cardial biopsy of myocarditis is infiltration of inflammatory cells such as neutro-
phils and mononuclear cells between myocardial fibers, and a necrotic lesion such
as rupture/melting of adjacent cardiomyocytes. The interstitium becomes edema-
tous and capillary angiogenesis occurs. The prevalence of cardiomyopathy during
whole heart failure varies by age and region, but ranges from approximately 0.5% to
4.0% [50]. Although about half of myocarditis patients are cured, sudden death due
to myocarditis is not uncommon.
3.7 Alcoholic cardiomyopathy
It is one of addictive cardiomyopathy caused by long-term and heavy drinking.
In general, it is estimated that the onset occurs when 80 to 90 g/day of pure ethanol
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equivalent is ingested daily for 5 years or more. Initially, diastolic dysfunction and
left ventricular hypertrophy occur, and then the left ventricle is dilated as it pro-
gresses of pathologic state. Treatment is complete abstinence first.
3.8 Left ventricular noncompaction cardiomyopathy
Left ventricular noncompaction cardiomyopathy (LVNC) is a structural abnor-
mality of the left ventricular myocardium of unknown cause. Since LVNC is asso-
ciated with genetic disease, particularly neuromuscular disorders (NMDs) and
chromosomal defects in the majority of patients, in the AHA cardiomyopathy
classification, LVNC is classified as one of the genetic primary cardiomyopathies
[5]. Mortality of patients with LVNC ranges from 5% to 47% [51]. LVNC is charac-
terized by a two-layered structure usually of the apical and lateral left ventricular
myocardium, distal to the papillary muscles. The two-layered structure consists of
an excessive spongy endocardial layer (noncompacted layer: NC) and a compacted
epicardial layer (compacted layer: C), which is usually thinner than the endocardial
layer and NC/C ratio is 2 or more by echocardiography. In LVNC, many genetic
abnormalities have been reported such as TAZ, DTNA and LDB3 gene mutation,
and many genetic abnormalities of sarcomere protein have also been reported [51].
LVNC is usually asymptomatic, but can be complicated by heart failure, thrombo-
embolism, or ventricular arrhythmias, including sudden cardiac death. LVNC is
diagnosed primarily by echocardiography, and is frequently associated with myo-
cardial fibrosis, as shown by the presence of late gadolinium enhancement (LGE)
on CMR [51, 52].
3.9 Beriberi heart
Vitamin B1 (thiamine) is a coenzyme essential for glucose metabolism. It is
thought that thiamine supplementation is insufficient due to high-calorie infusion
and unbalanced diet during the growth period, and then deficiency occurs [53]. If
this deficiency lasts for more than 3 months, beriberi occurs.
3.10 Mitochondrial cardiomyopathy
Mitochondrial disease is a multi-organ disease characterized by oxidative phos-
phorylation disorders caused by mitochondrial dysfunction due to mutations in the
nucleus and mitochondrial DNA. Therefore, mitochondrial cardiomyopathy is often
recognized as a symptom of mitochondrial disease. The prevalence of inherited
mitochondrial disease has been estimated to be greater than 1 in 5,000 births [54]. A
common pathology of mitochondrial cardiomyopathy is a decrease in mitochondrial
ATP production capacity per one cardiomyocyte [55]. Since the myocardium is an
organ that continuously consumes energy through aerobic metabolism, ATP defi-
ciency is directly linked to a decrease in myocardial contractility. Many nuclear and
mitochondrial DNA mutations associated with mitochondrial cardiomyopathy have
been reported. Typical mitochondrial diseases MELAS (mitochondrial myopathy，
encephalopathy，lactic acidosis and stroke-like episodes), MERRF (myoclonus epi-
lepsy associated with ragged-red fibers), CPEO (chronic progressive external
ophthalmoplegia), and KSS (Kearns-Sayre syndrome) also develop mitochondrial
cardiomyopathy. The typical cardiac manifestations of mitochondrial cardiomyop-




ventricular myocardial noncompaction, and heart failure, and may worsen rapidly
due to infection or sudden death due to lethal arrhythmia [55].
3.11 Anderson-Fabry disease
Anderson-Fabry disease (AFD) is an X-linked hereditary glycolipid metabolism
disorders due to deficient activity of the enzyme alpha-galactosidase A (α-Gal A)
located on the X-chromosome (Xq22.1) resulting in progressive lysosomal deposition
of globotriaosylceramide (GL-3) in cells throughout the body [56]. AFD is one of sex-
linked recessive inheritance diseases. This indicates that all hemizygous men are
affected, whereas their daughters are obligate heterozygous carriers. However, AFD
is a disease that is more likely to onset the disease in heterozygotes (female). In
female, it is thought that one of the two X chromosomes is inactivated. In a female
who is heterozygotes, when the rate of inactivation of the X chromosome with the
mutant allele is high, it is close to normal. On the other hand, when the rate of
inactivation of the X chromosome with normal allele is high, symptoms of AFD will
appear. Females with AFD tend to develop and diagnose symptoms later than males.
In classic of AFD, glycosphingolipid accumulates in organs throughout the body
especially in the skin, kidneys, nerves, eyes, and heart, on the other hand, a cardiac
variant phenotype or a renal variant phenotype lack systemic findings and present
with organ-specific symptoms [56, 57]. Since the heart is involved in up to 70% of
patients who have AFD, the diagnostic procurer of AFD include the cardiac diagnosis
strategy such as baseline ECG, echocardiography and CMR with or without symp-
toms. The typical cardiac manifestations of AFD often mimic hypertrophic cardio-
myopathy [58]. That is, it is recognized as a disease that causes cardiac hypertrophy
and is classified as one of secondary cardiomyopathy. So clinically, the distinction
between sarcometic HCM and AFD is extremely important. CMR is an excellent way
to non-invasively diagnose cardiac involvement in AFD. Non-contrast T1 mapping of
CMR significantly displays lower value in AFD, compared to healthy volunteers and
patients with other confounding diseases [59].
3.12 Peripartum cardiomyopathy
Peripartum cardiomyopathy is a dilated cardiomyopathy-like state in women
who have no history of heart disease during pregnancy or childbirth. In some cases,
severe heart failure associated with postpartum cardiomyopathy is developed.
Although the detailed mechanisms of postpartum cardiomyopathy are still
unknown, the causes are thought to be hemodynamic changes due to pregnancy,
preeclampsia, viral infections, allergies, nutritional disorders, etc. In Japan, the
prevalence of peripartum cardiomyopathy has been estimated 1 in 10,000 to
20,000 births [60]. This is a lower rate than that of the United States [61]. How-
ever, the prevalence rate is increasing year by year due to the aging of pregnant
women, improvement of reproductive technology, and improvement of cardiomy-
opathy diagnosis rate.
3.13 Cardiomyopathy in muscular dystrophy
Muscle dystrophy is heterogeneous group of disorders characterized by genetic
and progressive degeneration of skeletal muscle and muscle weakness [62]. In Japan
the overall incidence of this disease is estimated as 2 to 3 out of 100,000. Duchenne
muscular dystrophy (DMD), Becker muscular dystrophy (BMD) are X-linked
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recessive (Xp21), Emery- Dreifuss Muscular Dystrophy (EDMD) is X-linked reces-
sive (Xq28 in EDMD1, Xq26 in EDMD 6), Autosomal dominant (EDMD2; LMNA
gene at 1q21), autosomal recessive (EDMD3, also involving the LMNA gene at
1q21), Limb Girdle Muscular Dystrophy (LGMD) is usually autosomal recessive
(LGMD2C. 2D, 2E & 2F: sarcoglycanopathies; LGMD2I: mutation of fukutin-related
protein gene; 19q), Rarely autosomal dominant (LGDM1; 1B due to mutation of the
LMNA gene encoding lamin A/C), and Myotonic Dystrophy (DM) is autosomal
dominant: type 1 (DM1, Steinert’s disease): unstable expansion of CTG the myo-
tonic dystrophy protein kinase gene (DMPK) on chromosome 19q13.3, type 2
(DM2): CCTG tetranucleotide repeat expansion in intron 1 of the zinc finger pro-
tein 9 gene (ZNF9) on chromosome 3q21.3 [63]. Almost all DMD patients develop
cardiomyopathy early on, on the other hand, symptom progression in BMD patients
is slow but may present with severe heart failure [64, 65]. Cardiomyopathy in
EDMD patients develops in the same way as that of DMD patients [ 66]. LGMD
patients develop sinus node dysfunction, atrioventricular node dysfunction, ven-
tricular arrhythmias as cardiomyopathy manifestations [67]. Common cardiomy-
opathy manifestations in DM1 and DM2 patients are atrioventricular and
intraventricular conduction defects. Infra-hisian block is likely an important cause
of sudden death in these patients [68, 69].
4. Hypertrophic cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM) is the common primary cardiomyopathy,
with a prevalence of 1:500 persons [64]. It is defined as left ventricular hypertrophy
without chamber dilation and is caused by gene mutations that encode 8 sarcomere
proteins: beta-myosin heavy chain (MYH7), cardiac myosin-binding protein C
(MYPBC3), cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), cardiac actin
(ACTC), alpha-tropomyosin (TPM1), essential myosin light chain (MYL3) and
regulatory myosin light chain (MYL2) [70]. Mutations in MYH7 and MYPBC3 often
occur and account for approximately 50% of HCM cases, while mutations in
TNNT2, TNNI3, ACTC, TPM1, MYL3 and MYL2 collectively account for less than
20% of HCM cases [71]. Septal thickening predominates and may cause left ven-
tricular outflow tract obstruction or mitral valve dysfunction [65]. Phenotypic
expression is variable. Many patients with HCM are asymptomatic and are diag-
nosed during family screening, by incidentally after an abnormal result on electro-
cardiography. Presenting signs and symptoms most characteristic of HCM include
atypical chest pain and sudden cardiac death (SCD). Patients who are diagnosed
with HCM may have a family history of unexplained sudden cardiac death. ECG
often show left ventricular hypertrophy and Q waves, and echocardiography often
show hypertrophy of the left ventricle coupled with reduction in ventricular cham-
ber volume [66].
The natural history of HCM is quite variable. Signs and symptoms range from
none, to atrial fibrillation, heart failure, embolic stroke and SCD. In heart failure in
HCM, since decreased left ventricular diastolic function due to cardiac hypertrophy
is the basic pathology of HCM, three categories of HCM patients emerged [67]: (1)
patients with obstruction at all times, (2) patients without obstruction in the basal
state in whom obstruction could be provoked, (3) patients without obstruction in
whom obstruction could not be provoked. The severity of the outflow gradient is
related to prognosis, and diastolic failure is a common dysfunction of HCM patients
[68]. Ventricular fibrillation is one of cause of SCD in HCM. All patients with HCM




implantable cardioverter-defibrillator [69]. Additionally, these devices are
recommended for secondary prevention of SCD when there is any personal history
of ventricular fibrillation or sustained ventricular tachycardia [64]. Although the
main goals of therapy in HCM patients are to decrease exertional dyspnea and chest
pain and prevent SCD, about 25% of HCM patients achieve normal longevity.
Particular the MYPBC3 variant carries a good prognosis.
5. Arrthymogenic cardiomyopathy (ACM)
As mentioned in history of classification in cardiomyopathy, ARVC was one of
cardiomyopathies characterized by right ventricular enlargement, decreased right
ventricular wall contractility, and right ventricular tachycardia due to myocardial
cell shedding and fibrofatty replacement in right ventricle. However, although the
original article defines as disease phenotype characterized by predominant involve-
ment of right ventricular dysfunction, recent reports show increased left dominant
and biventricular forms. Therefore, the recent recognition of the term of ARVC has
been replaced by arrthymogenic cardiomyopathy (ACM) [72].
ACM is an inherited heart disease characterized pathologically by fibrofatty
myocardial replacement and clinically by prominent ventricular arrhythmias and
impairment of ventricular function including both ventricles. The classical ARVC
phenotype in ACM shows the right ventricle with fibrofatty infiltration, regional
dilatation and aneurysm formation at the right ventricular inflow tract, outflow
tract and the right ventricular apex which are called as triangle of dysplasia. Phe-
notype of left ventricular dominant type of ACM is characterized by the early left
ventricular (LV) involvement with arrhythmias prior to gross structural alterations,
on the other hand global RV function of this type is preserved. Biventricular ACM is
characterized by early involvement of both ventricles with disease progression
characterized by systolic impairment and biventricular dilation, with clinical fea-
tures of global congestive heart failure, and ventricular arrhythmias originating
from either ventricle at an early stage. Frequency of occurrence of ACM has been
estimated at 1:1000 to 5,000, and it often occurs in the 30s, and the Sudden Cardiac
Death in the Young |Ten Points to Remember disease declared by American College
of Cardiology includes ACM as ARVC [73–75]. In ACM, there are gene abnormali-
ties of the desmosome proteins which works in adhesion between cardiomyocytes,
and gene abnormalities in the ryanodine receptor (RyR2) gene, which is a Ca2 +
handling protein. The desmosomal complex is formed the trans-membrane proteins
(cadherins), desmocollin-2 (DSC2), desmoglein-2 (DSG2), desmoplakin (DSP), the
linker armadillo proteins plakoglobin (JUP) and plakophi-lin-2 (PKP2). JUP and
PKP2 are mediators between the cadherins and DSP. Mutations in PKP2, DSP, and
DSG2 are identified in up to 80% of confirmed pathogenic mutations. PKP2
accounts for 36–92% of mutations identified in desmosomal genes [72].
6. Restricted cardiomyopathy (RCM)
RCM is characterized by limited filling of one or both ventricles, reduced dia-
stolic volume, and normal or near-normal contractility and wall thickness [76].
Ventricular wall thickness and contractility are almost normal, but diastolic volume
decreases due to decreased myocardial compliance, resulting in heart failure.
Endocardial fibrotic thickening and myocardial fibrosis may also be present.
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7. Treatment of cardiomyopathy
7.1 Medical treatment of cardiomyopathy
Treatment of symptomatic heart failure associated with various cardiomyopathy
should follow current guideline for the management of heart failure from American
College of Cardiology/American Heart Association or guidelines for the diagnosis
and treatment of acute and chronic heart failure from European Society of Cardiol-
ogy [77, 78]. Beta blocker, angiotensin-converting enzyme inhibitor (ACEi), angio-
tensin receptor blocker (ARB), diuretics, angiotensin receptor-neprilysin inhibitor
(ARNI), or sodium/glucose cotransporter 2 (SGLT2) blocker are used as pharma-
cologic therapy, when cardiomyopathy is associated with systolic dysfunction [79].
Patients with more severe heart failure symptoms should be evaluated for place-
ment of an implantable cardioverter-defibrillator, and may require cardiac trans-
plantation in refractory cases.
7.2 Mavacamten: new treatment for HCM
Mavacamten selectively inhibits cardiac myosin ATPase leading to reducing
actin–myosin cross-bridge formation [80]. As a result, it is expected that
mavacamten will improve pathophysiology of hypertrophic cardiomyopathy such
as left ventricular outflow tract (LOVT) obstruction, decreased left ventricular
filling. In preclinical and early clinical studies of mavacamten succeeded reduction
of LVOT gradients and improved parameters of left ventricular filling [81, 82]. In
the phase 2, PIONEER-HCM study revealed that mavacamten was well tolerated
and significantly reduced post-exercise LVOT gradients in obstructive HCM [83].
On the basis of these results, the short-term results of the phase 3 EXPLORER-HCM
trial have been published. EXPLORER-HCM was a phase 3, multicentre,
randomised, double-blind, placebo-controlled trial [84]. Eligible patients were aged
at least 18 years with a diagnosis of obstructive HCM; peak LVOT gradient at least
50 mm Hg at rest, after Valsalva manoeuvre or exercise; left ventricular ejection
fraction (LVEF) at least 55%; and NYHA class II–III symptoms. The patients had to
be able to safely perform upright cardiopulmonary exercise testing (CPET). Finally,
429 adults were assessed for eligibility, of whom 251 (59%) were enrolled. In the
placebo group, post-exercise LVOT gradient had changed from 84mmHg to
73mmHg after 30weeks, meanwhile that of the mavacamten group improved from
86 mmHg to 38 mmHg (difference from the placebo group: -36 mmHg, 95% CI:-
43.2 to -28.1 mmHg, P <0.0001). The average increase in pVO2 was also signifi-
cantly greater in the mavacamten group than in the placebo group (1.4 mL / kg /
min, 95% CI: 0.6-2.1 mL/kg/min, P = 0.0006). The number of patients whose
NYHA classification improved by 1 degree or more was 40 of 128 (31%) in the
placebo group and 80 of 123 (65%) in the mavacamten group (difference between
groups: 33.8%, 95% CI: 22.2-45.4%, P <0.0001). Treatment with mavacamten
improved exercise capacity, LVOT obstruction, NYHA functional class, and health
status in patients with obstructive HCM. EXPLORER-HCM trial is ongoing to assess
long-term (5 year) efficacy and safety.
7.3 Surgery for dilated and hypertrophic cardiomyopathy
Cardiomyopathy is categorized as a disease of the cardiomyocytes and is com-




Moreover, mitral valve regurgitation (MR) and ventricular arrhythmia are com-
monly associated with cardiomyopathy. Surgical treatment for cardiomyopathy is a
combination of maneuvers on the ventricle, mitral annulus and leaflets. We herein
summarize the current surgical management of dilated and hypertrophic obstruc-
tive cardiomyopathy (HOCM).
7.4 Hypertrophic cardiomyopathy
In patients with HOCM, heart failure is caused by left ventricular outflow tract
(LVOT) obstruction, mitral valve dysfunction due to systolic anterior motion and
diastolic dysfunction. Surgical treatment should relieve such dysfunctions, and the
use of a mitral prosthetic valve should be avoided if possible.
7.4.1 Procedures on the left ventricle
Septal hypertrophy is a typical physiological feature of HOCM. Echocardiogra-
phy during exercise is a reliable diagnostic modality and could provide significant
prognostic information [85]. Peteiro and colleagues reported that, as only 13% of
patients presented with LVOT obstruction at rest, 27% developed exercise-induced
LVOT obstruction [85]. Cui and colleagues proved that septal hypertrophy with a
significant LVOT pressure gradient truly generated obstruction of blood flow to the
aorta [86]. Different from aortic valve stenosis, increased LVOT gradient caused
decreased stroke volume [86]. In addition, the efficacy of septal myectomy was
compared with valvular aortic stenosis. After myectomy with a normalized LVOT
gradient, the aortic flow pattern returned to normal [86]. Therefore, septal
myectomy is the principal surgical maneuver for HOCM. The improvement in
stroke volume after myectomy explains the improvement in exercise capacity post-
operatively [86]. Furthermore, Parbhudayal and colleagues compared myectomy
for HOCM with aortic valve replacement for valvular stenosis and reported reverse
remodeling after surgery [87]. They reported that recovery of systolic function was
only observed after aortic valve replacement, while patients with HOCM demon-
strated systolic functional deterioration, which was a negative impact of septal
myectomy on cardiac function and was associated with ongoing pathophysiological
conditions [87].
The spectrum of HOCM is of great variety in terms of location and severity of
hypertrophy, positional relationship between the septum and anterior mitral leaflet
and papillary muscles. For patients with mid-ventricular hypertrophy, broad
myectomy concomitant with mitral valve replacement is necessary to relieve dila-
tation dysfunction.
7.4.2 Procedures on the mitral valve
Both ventricular hypertrophy and structural abnormalities of the mitral valve
are frequently found in HOCM. An elongated anterior mitral leaflet is commonly
associated with systolic anterior motion and MR. Regarding surgery for MR,
analysis of the Society of Thoracic Surgeons database suggested that mitral etiology
was not significantly associated with an incremental risk of early mortality [88].
Systolic anterior motion is associated with anomalously elongated anterior mitral
leaflet. Balaram and colleagues recommended that the standard maneuver for the
mitral leaflet was horizontal plication through the aortic valve when the anterior
mitral leaflet was elongated by 30 mm, and the standard technique is plication of the
leaflet, usually performed through the aortic valve [89, 90]. The plication can shorten
the leaflet length by 2–5 mm [91]. Recently, the edge-to-edge technique was reported
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to be useful in HOCM and can be applied through either the aortic valve [92] or the
left atrium [93]. Chordal cutting was also reported to be effective for relieving LVOT
obstruction through geometric modification [94].
Septal myectomy is the primary maneuver for HOCM. In addition to myectomy,
the maneuvers for the leaflet and sub-valvular apparatus are viable surgical options,
especially when septal hypertrophy is not severe.
7.5 Idiopathic and ischemic dilated cardiomyopathies
For ischemic cardiomyopathy, MR was commonly found without any prolapse
or deformity of the leaflets and chordal elongation or rupture. Such MR is usually
functional and associated with apical displacement of the papillary muscles and
dilatation of the mitral annulus. The presence of MR causes heart failure during
follow-up and significantly worsens patient prognosis. Therefore, it has been widely
accepted that surgical management of MR is crucial.
7.5.1 Procedures on the mitral valve
Ischemic or dilated cardiomyopathy causes functional MR. Patients have severe
dilatation of the left ventricle, which causes mitral annular dilatation, leaflet teth-
ering and the gap between the leaflets. Consequently, severe MR causes volume
overload, fibrosis and adverse remodeling of the ventricle [95, 96].
During mitral valve repair, annuloplasty is frequently performed for ischemic
cardiomyopathy. In the procedure, the artificial full and semi-rigid ring is
implanted to reduce the annular diameter. Noack and colleagues reported that even
for patients with poor ventricular ejection fraction of <30%, mitral valve repair
could be safely performed [97]. Xu and colleagues reported that under-sizing
annuloplasty was effective for eliminating MR [98]. Kainuma and colleagues
reported favorable remodeling, decreased tethering distance and inter-papillary
muscle distance during the follow-up period [99]. Conversely, choosing a
downsized artificial ring might cause functional mitral stenosis and recurrence of
MR compared with mitral valve replacement [100]. In some cases, ventricular or
sub-valvular reconstruction procedures are necessary to achieve successful and
durable mitral valve repair.
7.5.2 Procedures on the left ventricle
In ischemic cardiomyopathy, surgical coronary revascularization is beneficial to
achieve favorable remodeling after surgery and avoid clinical outcomes [101].
Surgical ventricular reconstruction (SVR) such as the Dor procedure and its modi-
fications contributed to improved long-term clinical outcomes with a reasonable
perioperative risk [102]. Moreover, appropriate surgical maneuver of SVR had a
significant impact on prognosis after surgery [102]. However, the clinical advantage
of SVR concomitant with coronary artery bypass graft was not demonstrated in the
STICH (Surgical Treatment for ischemic Heart Failure) trial, which was a
randomized study of SVR in ischemic cardiomyopathy [103]. Patient selection for
SVR may be an issue in the future.
7.5.3 Summary of surgery for dilated and hypertrophic cardiomyopathy
The clinical and morphological manifestations of cardiomyopathy vary greatly




the ventricle are not necessarily beneficial in the long-term follow-up. Surgical
treatment for cardiomyopathy should be individualized for patients.
8. iPS cell development from DCM heart
Induced pluripotent stem (iPS) cell development is one of the most promising
technologies in regenerative medicine [104]. iPS cell is evoked via the epigenetic
silencing of somatic cells by the Yamanaka factors, i.e., the four transcription
factors Oct4, Sox2, Klf4, and c-Myc. Advances in iPS cell reprogramming technol-
ogy could allow aging or damaged cells to be replaced by the patient’s own rejuve-
nated cells; therefore, the clinical application of iPS cell reprogramming technology
may be a solution to the problem of age-related degenerative diseases. However,
senescent or pathologic tissue has a relatively low reprogramming efficiency com-
pared with juvenile or robust tissue, resulting in incomplete cell reprogramming.
Our laboratory developed a new reprogramming method for generating iPS cells
using pathologic somatic cells from a recipient heart that states the severe heart
failure associated with DCM [105].
For gene transfection of iPS cell differentiation, in addition to the Yamanaka
factors, GLIS1 and TET-1 were added. Gli-similar transcription factors (Glis)
belong to the group of Krüppel-like zinc-finger transcription factors, and three
GLIS genes (GLIS1–3) have been identified [106]. Yoshioka et al. reported that
Yamanaka factor RNAs with Glis-1 RNA that were purified from an RNA-
replicative vector yielded high-efficiency iPS cell reprogramming from older adult
human cells [107]. Tet-1, which is one of DNA demethylase, contributes to the
differentiation of the inner cell mass at the blastocyst stage and regulates the
maintenance of ES cells by altering the DNA methylation status [108]. Olariu et al.
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cocktail and that DNA methylation is the key to regulating pluripotency genes
[109]. Since Tet-1 may also evoke the induction of Dnmt3b expression upon tran-
sition to the epiblast stage, TET-1 was included in the final set of six genes to be
transfected in our protocol.
Cardiac fibroblasts obtained from a recipient heart highly expressed α-smooth
muscle actin (α-SMA) that is a representative marker of myofibroblast.
Myofibroblasts occur at a converging spot of mesenchymal cells, resulting from
acute or chronic inflammation caused by stimulation with TGF-β, Ang II, and
cytokines [110]. Interestingly, the myofibroblasts from our patient’s heart tissue did
not differentiate into human iPS cells by previous methods [111]. Therefore, the cell
culture medium for iPS cell induction was also prepared in detail. During the first 5
days post-transfection, TGF-β was removed from the cell culture medium for iPS
cell induction, and selective TGF-β inhibitor SB431542 was added. Finally, by com-
bining these methods, we developed a highly efficient method for inducing human
iPS cells from pathologic somatic cells (Figure 5) [105].
9. Summary of cardiomyopathy recent findings
We outlined the recent findings of cardiomyopathy. In addition to the develop-
ment of the cardiac devices and regenerative medicine, clinical trials of heart failure
drugs such as ARNI, SGLT2 inhibitors and cardiac function improving drugs as
mavacamten have shown effective results leading to desirable situation for cardiol-
ogists to expand their options. Our goal is to improve the QOL of cardiomyopathy
patients.
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